From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
Trade names Neupramir, Pramistar, Remen
AHFS/ International Drug Names
Legal status Unscheduled (US)
Routes Oral
Pharmacokinetic data
Half-life 4.5-6.5 hours
CAS number 68497-62-1 N
ATC code N06BX16
PubChem CID 51712
ChemSpider 46801 YesY
UNII 4449F8I3LE YesY
Chemical data
Formula C14H27N3O2 
Mol. mass 269.383 g/mol
 N (what is this?)  (verify)

Pramiracetam is a nootropic drug derived from piracetam, and is more potent (i.e. lower dosage is used)[citation needed]. It belongs to the racetam family of nootropics, and goes by the trade name Remen (Parke-Davis), Neupramir (Lusofarmaco) or Pramistar (Firma).[1] Pramiracetam is used off-label for a wide range of applications.


Pramiracetam was developed by Parke-Davis in the late 1970s. The first patents for this drug appeared in 1978 (Belgium) and 1979 (US), concurrent with its first reporting of nootropic characteristics.

Side effects[edit]

Pramiracetam, like other members of the racetam family, is generally well tolerated by humans[citation needed]. In a study where a small sample of human subjects with varying degrees of Alzheimer's disease were treated for 5–8 weeks, symptoms were few and mild. At relatively low dosages, a few participants reported headaches. One participant at the highest end of the dosage spectrum experienced sleepiness, decreased appetite, and dizziness[citation needed]. In another study where a small sample of healthy, male human subjects were treated for 10 days, no adverse events were reported.[2][citation needed]


  1. ^ Axel Kleemann, Jürgen Engel, Bernd Kutscher und Dietmar Reichert: Pharmaceutical Substances, 4. Edition (2000), ISBN 978-1-58890-031-9
  2. ^ "Pramiracetam: Smarter Nootropics". March 30, 2012. Retrieved April 11, 2012. 

External links[edit]